Enhancing Equitable Health Product Roll-out in Low- and Middle-Income Countries
Strategies to enhance equitable access to health products in low- and middle-income countries will be discussed at the AIDS 2022 conference, focusing on key factors such as availability, acceptability, affordability, accessibility, and quality. The Medicines Patent Pool aims to increase access to in
0 views • 14 slides
Impact of Antiretroviral Treatment on Weight and Obesity in HIV Patients
Dolutegravir (DTG) treatment has shown associations with weight gain and clinical obesity, particularly in black individuals and women. In contrast, tenofovir disoproxil fumarate (TDF) is linked to lower body weight compared to other treatments. Trials like ADVANCE and NAMSAL have provided insights
0 views • 31 slides
Dolutegravir-Lamivudine Dual Therapy in ARV-Naïve HIV Patients: 48-Week Results of PADDLE Trial
The PADDLE trial evaluated the efficacy, safety, and tolerability of a Dolutegravir-Lamivudine regimen as initial therapy in HIV-infected, treatment-naïve patients. This pilot study demonstrated comparable viral load changes to triple therapy, supporting the use of this dual regimen. The study desi
0 views • 13 slides